[{"indications": "Indications\u00a0%s\n(From 8.3.4.3 Somatostatin analogues: British National Formulary)\n8.3.4.3 Somatostatin analogues", "name": "LANREOTIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.3 Sex hormones and hormone antagonists in malignant disease", "8.3.4 Hormone antagonists", "8.3.4.3 Somatostatin analogues", "LANREOTIDE"], "cautions": "Cautions\u00a0\n(From 8.3.4.3 Somatostatin analogues: British National Formulary)\n8.3.4.3 Somatostatin analogues; cardiac disorders (including bradycardia); interactions: Appendix 1 (lanreotide)", "side-effects": "Side-effects\u00a0\n(From 8.3.4.3 Somatostatin analogues: British National Formulary)\n8.3.4.3 Somatostatin analogues; also reported\r\nconstipation, dyspepsia, bradycardia, asthenia, dizziness, fatigue,\r\nraised bilirubin, biliary dilatation, alopecia; less commonly skin nodule, hot flushes, leg pain, malaise, headache, insomnia,\r\ntenesmus, decreased libido, drowsiness, pruritus, increased\r\nsweating; rarely hypothyroidism (monitor as necessary)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106502.htm", "doses": ["See under preparations", "by deep subcutaneous injection into the\r\ngluteal region, acromegaly (if somatostatin analogue not given previously),\r\ninitially 60\u00a0mg every 28 days, adjusted according to response; for\r\npatients treated previously with somatostatin analogue, consult product\r\nliterature for initial dose"], "pregnancy": "Pregnancy\u00a0manufacturer advises use only if potential benefit\r\noutweighs risk"}]